XERS Xeris Biopharma Holdings Forecast, Technical & Fundamental Analysis
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States... Show more
XERS is expected to report earnings to fall 77.33% to 1 cents per share on August 06
Q2'26
Est.
$0.01
Q4'25
Beat
by $0.04
Q3'25
Missed
by $0.01
Q2'25
Beat
by $0.02
Q1'25
Missed
by $0.01
The last earnings report on March 02 showed earnings per share of 5 cents, beating the estimate of 1 cents. With 322.75K shares outstanding, the current market capitalization sits at 1.19B.
A.I. Advisor
published General Information
General Information
a developer of ready-to-use, liquid-stable injectables
A.I.dvisor indicates that over the last year, XERS has been loosely correlated with MIRM. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if XERS jumps, then MIRM could also see price increases.
The Moving Average Convergence Divergence (MACD) for XERS turned positive on June 09, 2026. Looking at past instances where XERS's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 08, 2026. You may want to consider a long position or call options on XERS as a result. In of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
XERS moved above its 50-day moving average on June 04, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where XERS advanced for three days, in of 241 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for XERS moved out of overbought territory on June 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 40 similar instances where the indicator moved out of overbought territory. In of the 40 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XERS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
XERS broke above its upper Bollinger Band on June 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for XERS entered a downward trend on June 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. XERS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (90.909) is normal, around the industry mean (144.224). P/E Ratio (98.286) is within average values for comparable stocks, (97.846). XERS's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.594). XERS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.033). P/S Ratio (3.912) is also within normal values, averaging (95.956).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
